Fig. 1From: Soluble TIM-3, likely produced by myeloid cells, predicts resistance to immune checkpoint inhibitors in metastatic clear cell renal cell carcinomasTIM-3 plasma levels in ccRCC patients. sTIM-3 plasma levels were measured in treatment-naive ccRCC patients from the BIONIKK cohort before ICI treatment, and in healthy adultsBack to article page
